CHMP issues positive opinion to expand INVOKANA & VOKANAMET labels to include positive data on cardiovascular(CV) & renal outcomes

 CHMP issues positive opinion to expand INVOKANA & VOKANAMET labels to include positive data on cardiovascular(CV) & renal outcomes

CHMP issues positive opinion to expand INVOKANA & VOKANAMET labels to include positive data on cardiovascular(CV) & renal outcomes

Shots:
  • Mundipharma has gained exclusive distribution rights from Janssen for Europe and Switzerland excluding Spain
  • The drug is recommended for Type 2 Diabetes Mellitus (T2DB) patients with adverse CV disease or atleast 2 CV risk factors
  • The Type 2 variation application is based on CANVAS programme included 10,000 patients treated since 2009, showed reduction in CV death, myocardial infarction and non-fatal stroke VS placebo in adults with T2DB
Click here to read full press release/ article | Ref: Mundipharma | Image: Mundipharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post